Pfizer-backed UK biotech raises £25M to advance mitophagy pipeline
Mission announces publication outlining potential of experimental drug MTX325
CAMBRIDGE, England--(BUSINESS WIRE)--Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the successful completion of its first Phase I clinical assessment for lead USP30 DUB inhibitor, MTX652.
Safety, tolerability and pharmacokinetic endpoints for MTX652 have been successfully met
CAMBRIDGE, England--(BUSINESS WIRE)--Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), announces that CEO, Dr Anker Lundemose, will present at the upcoming J.P Morgan Healthcare Conference.